Cancer Treatment Reviews

Mar 26, 2023 | cancertreatmentreviews.com | Aakash Desai |Solange Peters

Herbst R.S. Baas P. Kim D.-W. Felip E. Pérez-Gracia J.L. Han J.-Y. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016; 387: 1540-1550Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?. Journal of general internal medicine. 2021; 36: 3202-3204Desai A. Velazquez A.I. West H. Perioperative Therapy in Early-Stage Lung Cancer. JAMA.

Mar 16, 2023 | cancertreatmentreviews.com | Víctor Navarro

Mar 3, 2023 | cancertreatmentreviews.com | Tim Schutte |Amsterdam UMC |location VUmc |Alaa Embaby

[40]Chen A.P. Kummar S. Moore N. et al. Molecular profiling-based assignment of cancer therapy (NCI-MPACT): A randomized multicenter phase II trial.

Feb 23, 2023 | cancertreatmentreviews.com | Volkmar Müller |Rupert Bartsch |Nancy Lin |Filippo Montemurro

Monoclonal antibodyNCT01004172*[54]Leone J.P. Emblem K.E. Weitz M. Gelman R.S. Schneider B.P. Freedman R.A. et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Phase 2, single-arm, open-label trialBevacizumab (monotherapy 15 mg/kg IV on cycle 1 day 1) + carboplatin (IV, AUC = 5, on cycle 1 day 8; HER2– cohort only). Patients with HER2-positive disease also received trastuzumab (8 mg/kg load if indicated; otherwise, 6 mg/kg on cycle 1 day 8).

Dec 28, 2022 | cancertreatmentreviews.com | Zev A. Wainberg